Management
Erez AminovChairman and CEO
Erez Aminov is the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company pioneering age-reversal science. Under his leadership, Telomir has advanced innovative therapies targeting age-related conditions, including Type 2 Diabetes, aging, and Progeria—a rare and fatal genetic disorder characterized by accelerated aging in children. Mr. Aminov has successfully guided Telomir through multiple preclinical trials, secured critical funding, and built a high-performing team dedicated to advancing transformative solutions in regenerative medicine.
In addition to his leadership at Telomir, Mr. Aminov serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a biopharmaceutical company developing groundbreaking treatments for neuropsychiatric disorders. At MIRA, he has been instrumental in advancing key therapies such as MIRA55 and Ketamir-2, securing funding, and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field.
With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceuticals and Telomir Pharmaceuticals, demonstrating his expertise in navigating complex regulatory and financial landscapes.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of strategic vision, financial expertise, and commitment to advancing life-changing therapies has positioned Telomir Pharmaceuticals at the forefront of age-reversal science.
In addition to his leadership at Telomir, Mr. Aminov serves as Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a biopharmaceutical company developing groundbreaking treatments for neuropsychiatric disorders. At MIRA, he has been instrumental in advancing key therapies such as MIRA55 and Ketamir-2, securing funding, and leading the company to the submission of an Investigational New Drug (IND) application. His strategic guidance played a central role in MIRA’s successful initial public offering (IPO), establishing it as a leader in its field.
With a wealth of experience in biotechnology consulting, investment, and leadership, Mr. Aminov also founded Locate Venture Corp, where he supported early-stage biotech enterprises. He has been a driving force behind the IPOs of both MIRA Pharmaceuticals and Telomir Pharmaceuticals, demonstrating his expertise in navigating complex regulatory and financial landscapes.
Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of strategic vision, financial expertise, and commitment to advancing life-changing therapies has positioned Telomir Pharmaceuticals at the forefront of age-reversal science.
Alan Weichselbaum, CPA, MBAChief Financial Officer
Alan Weichselbaum, CPA, MBA, currently serves as Chief Financial Officer of both Telomir Pharmaceuticals, Inc. and MIRA Pharmaceuticals, Inc., bringing over 30 years of experience in corporate finance, capital markets, and strategic advisory across multiple industries. He plays a key leadership role in advancing the financial and strategic objectives of both companies as they pursue growth through drug development, licensing, and potential M&A opportunities.
Since 2015, Mr. Weichselbaum has served as a Director of FinWise Bancorp (Nasdaq: FINW), providing oversight and strategic direction to the publicly traded financial institution. In 2011, he founded The Wexus Group, an outsourced CFO advisory firm that partners with small and mid-sized companies to support growth, capital structuring, and exit strategies across various sectors.
From 1995 to 2010, he held senior roles on Wall Street, where he served as an equity analyst, managed two hedge funds, and was Chief Executive Officer of a boutique brokerage firm. His capital markets expertise and experience leading institutional transactions have positioned him as a trusted advisor in both public and private markets.
Earlier in his career, Mr. Weichselbaum was Manager of Budgeting and Financial Analysis at Philip Morris Capital Corporation. He began his professional journey at Price Waterhouse in 1985, working in the firm’s small business division before pursuing graduate studies.
Mr. Weichselbaum earned his MBA in Finance from New York University and is a Certified Public Accountant licensed in the State of New York. His deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at both Telomir and MIRA Pharmaceuticals.
Since 2015, Mr. Weichselbaum has served as a Director of FinWise Bancorp (Nasdaq: FINW), providing oversight and strategic direction to the publicly traded financial institution. In 2011, he founded The Wexus Group, an outsourced CFO advisory firm that partners with small and mid-sized companies to support growth, capital structuring, and exit strategies across various sectors.
From 1995 to 2010, he held senior roles on Wall Street, where he served as an equity analyst, managed two hedge funds, and was Chief Executive Officer of a boutique brokerage firm. His capital markets expertise and experience leading institutional transactions have positioned him as a trusted advisor in both public and private markets.
Earlier in his career, Mr. Weichselbaum was Manager of Budgeting and Financial Analysis at Philip Morris Capital Corporation. He began his professional journey at Price Waterhouse in 1985, working in the firm’s small business division before pursuing graduate studies.
Mr. Weichselbaum earned his MBA in Finance from New York University and is a Certified Public Accountant licensed in the State of New York. His deep financial acumen, combined with extensive experience in investor relations, capital formation, and M&A, makes him a vital member of the executive leadership at both Telomir and MIRA Pharmaceuticals.
Itzchak Angel, PhDChief Scientific Advisor
Itzchak Angel is an accomplished executive in the pharmaceutical industry, with over 40 years’ experience guiding medical, pharmaceutical, drug and business development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.) where he assists pharmaceutical and biotechnology companies, individuals, medical staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development. In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors, and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business development, and organizational planning.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.
Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.
Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.
Francis E. O'Donnell, Jr., MDSenior Advisor
Dr O’Donnell is our scientific advisor. As such he is part of the team that is responsible for strategy, direction, and execution of the Company’s clinical development plans. In addition, he works with senior management to evaluate the scientific, and clinical viability of potential products, assessing their commercial potential to address unmet medical indications taking into account approved drugs as well as drugs under development by competitors. Dr. O’Donnell has thirty years of experience in pharmaceutical development.
He received his BA from Johns Hopkins University’s accelerated program and his MD from Johns Hopkins University School of Medicine, as well as his specialty and fellowship training. He is an inventor or co-inventor on over 40 US patents.
He received his BA from Johns Hopkins University’s accelerated program and his MD from Johns Hopkins University School of Medicine, as well as his specialty and fellowship training. He is an inventor or co-inventor on over 40 US patents.